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Abstract   
Objective 
Neutrophil recruitment is a key process in the pathogenesis of stroke, and may provide a 
valuable therapeutic target. Targeting the melanocortin receptors (MC) has previously shown 
to inhibit leukocyte recruitment in peripheral inflammation, however it is not known whether 
treatments are effective in the unique cerebral microvascular environment. Here, we provide 
novel research highlighting the effects of the melanocortin peptides on cerebral neutrophil 
recruitment, demonstrating important yet discrete roles for both MC1 and MC3. 
Approach and Results 
Using intravital microscopy, in two distinct murine models of cerebral ischemia-reperfusion 
(I/R) injury we have investigated melanocortin control over neutrophil recruitment. Following 
global I/R, pharmacological treatments suppressed pathological neutrophil recruitment. MC1 
selective treatment rapidly inhibited neutrophil recruitment while a non-selective MC agonist 
provided protection even when co-administered with an MC3/4 antagonist, suggesting the 
importance of early MC1 signaling. However by 2h reperfusion, MC1 mediated effects were 
reduced, and MC3 anti-inflammatory circuits predominated. Mice bearing a non-functional 
MC1 displayed a transient exacerbation of neutrophil recruitment following global I/R, which 
diminished by 2h. However importantly, enhanced inflammatory responses in both MC1 
mutant and MC3-/- mice resulted in increased infarct size and poor functional outcome 
following focal I/R. Furthermore we utilized an in vitro model of leukocyte recruitment to 
demonstrate these anti-inflammatory actions are also effective in human cells. 
Conclusions 
These studies reveal for the first time melanocortin control over neutrophil recruitment in the 
unique pathophysiological context of cerebral I/R, whilst also demonstrating the potential 
therapeutic value of targeting multiple MCs in developing effective therapeutics. 
 
Abbreviations 
BCCAo - Bilateral common carotid artery occlusion, EC - Endothelial cell, e/e - MC1 mutant 
recessive yellow e/e, I/R - Ischemia-reperfusion, IVM - Intravital microscopy, L-E - Leukocyte 
- endothelial cell, MC - Melanocortin Receptor, MC3-/- - Melanocortin receptor 3 null, MCAo – 
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Introduction 
Inflammation plays a central role in cerebral I/R injury. Infiltrating neutrophils contribute to a 
highly neurotoxic milieu as illustrated by the reduced infarct size and improved functional 
outcome in models of cerebral I/R following depletion of circulating neutrophils1. Anti-
inflammatory strategies focused on inhibiting neutrophil recruitment by blocking adhesion 
molecules have however thus far proven ineffective in clinical trials1. The most probable 
limiting factor to such therapies is that the inflammatory response is a robust system, 
propagated by diverse pathways, and as such, cannot be effectively subdued by neutralizing 
a single component. Thus, harnessing endogenous mechanisms for the resolution of 
inflammation, which impact multiple elements of the inflammatory response, may provide a 
fruitful strategy. 
Five G-protein coupled melanocortin receptors (MC1-5) and the endogenous agonists, 
adrenocorticotrophic hormone, α, β and γ melanocyte-stimulating hormones (MSH) make up 
the melanocortin receptor system 2. Over the last fifteen years, research by our team has 
been pivotal in helping to unravel the biological effects of peptides within this system 
demonstrating robust anti-inflammatory actions in a number of inflammatory situations 
including gouty, rheumatoid, osteoarthritis as well as in cardiovascular and I/R models 3-5. 
These actions are proposed to be mediated primarily through inhibition of NF-κB. 
Furthermore, leukocytes are both a target for, and source of, melanocortins suggesting that 
the melanocortin receptor system may provide a self-limiting anti-inflammatory loop, serving 
to promote inflammatory resolution2. Such pleiotropic anti-inflammatory actions make these 
receptors a promising therapeutic candidate to address aberrant inflammation in stroke6. 
Of the five MCs identified, anti-inflammatory actions have been attributed primarily to MC1 
and MC32. These receptors have both been shown to be expressed at varying levels in the 
brain and also on endothelial cells and immune cells (MC1 expression on neutrophils; 
monocytes and macrophages; dendritic cells; natural killer cells and B lymphocytes. MC3 
expression on monocytes; macrophages and B lymphocytes)2. However, the exact anti-
inflammatory role of MC subtypes remains unclear, and may vary with the 
pathophysiological environment.  
In this study, we utilize two distinct murine models of cerebral I/R to evaluate the dynamic 
recruitment of neutrophils in the cerebral microcirculation. Using both pharmacological and 
genetic approaches, we have demonstrated potent inhibitory actions of the melanocortins on 
cerebral leukocyte trafficking, and gained an insight into the relative importance of MC 
subtypes in mediating these effects. 
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Materials and Methods 
 
Materials and Methods are available in the online-only data supplement. 
 
Results 
α-MSH abrogates neutrophil recruitment following cerebral I/R 
To investigate leukocyte recruitment in the cerebral microvasculature, global ischemia was 
induced, followed by 40min or 2h reperfusion and leukocyte to endothelial cell (L-E) 
interactions in pial vessels were assessed by IVM (Figure 1). Sham surgery, produced little 
to no leukocyte recruitment, however I/R caused significant leukocyte rolling 
(191.0±31.49cells/mm2/min) and adherence (282.3±49.4cells/mm2/min), with 2h reperfusion 
resulting in a further significant increase in adhesion to 555.2±85.3cells/mm2/min (Figure 1C, 
supplemental video I and II). Correlating with the observed effects on leukocyte recruitment 
was an enhanced serum soluble E-selectin by 2h reperfusion, as detected by ELISA, and a 
trend toward an increase in the number of ICAM-1 and VCAM-1 positive vessels detected in 
the brain. No effect was observed with respect to soluble P-selectin (supplemental figure II). 
α-MSH (10µg i.p.), a non-selective MC agonist, given at the start of reperfusion strongly 
inhibited leukocyte recruitment at 40min, reducing rolling by 80% and adhesion by 68%, to 
levels comparable to sham animals. Furthermore these protective effects remained highly 
significant even after 2h of reperfusion (supplemental video III). In line with the reduced 
leukocyte recruitment at 2h, α-MSH was also found to reduce levels of soluble E-selectin 
and a modest reduction in vessel ICAM-1and VCAM-1 expression. 
 
Finally, in order to ascertain the role of neutrophils, some mice were depleted of neutrophils 
prior to I/R. Following I/R, neutropenic mice displayed significant reductions of leukocyte 
rolling (81%) and adhesion (76%), consistent with the majority or all cells observed being 
neutrophils (Supplemental Figure I). 
 
Effect of α-MSH on NF-κB related cytokine and mRNA expression 
The effect of cerebral I/R on serum cytokines was investigated using multi-cytokine analysis 
(Supplemental Figure IIIA-C). Expression of IL-12p70, IFN-γ and MCP-1 remained below the 
reliable detection range across all treatments (Data not shown). I/R induced a significant 
increase in serum TNF-α by 2h, which was abolished by α-MSH treatment. The anti-
inflammatory cytokine IL-10 showed a trend toward an increase at 2h reperfusion (to 
34.7pg/ml), but significantly increased (88.7pg/ml) following α-MSH treatment. Levels of the 
pleotropic cytokine IL-6 remained unchanged following I/R, however treatment with α-MSH 
was found to result in a significant up-regulation of IL-6 by 2h. Considering IL-6 signaling via 
STAT3 has been shown to reduce neutrophil recruitment27, we also investigated levels of 
tyrosine 705 phosphorylated STAT-3 in leukocyte nuclear fractions by western blot, finding a 
slight enhancement of STAT3 in α-MSH treated animals at 2h (supplemental figure IV). 
 
To investigate whether this influence over serum cytokines could be due to NF-κB inhibition, 
mRNA levels of the NF-κB regulatory protein IκB (which closely corresponds to NF-κB 
activation7) were assessed in both blood and brain using qRT-PCR (Supplemental Figure 
IVA and B). IκB levels were not significantly elevated 40min following I/R, however by 2h, 
IκB was significantly increased in the blood, and this was suppressed by α-MSH treatment. 
Suppression of NF-κB activation in leukocytes at 2h reperfusion was further confirmed by 
western blot analysis of serine 536 phophorylated NF-kB p65 in leukocyte nuclear fractions. 
 
Effect of MC1 and MC3 agonists on neutrophil recruitment and circulating cytokines  
The relative contribution of MC subtypes on IR induced neutrophil recruitment was 
investigated using more selective MC agonists. Activation of MC1 by BMS-470539 provided 
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a potent inhibition of BCCAo induced neutrophil rolling and adhesion at 40min reperfusion 
(Figure 2A and B) however, became less effective by 2h, with only the level of adhesion 
being significant vs. vehicle. On the other hand, treatment with [DTRP8]-γ-MSH, which has a 
high affinity for MC3, only inhibited cell adhesion at 40min reperfusion, yet by 2h this effect 
was stronger, with neutrophil rolling also being significantly reduced. Furthermore [DTRP8]-γ-
MSH significantly reduced BCCAo induced TNF-α release by 2h whilst also elevating serum 
levels of the pleiotropic cytokine IL-6 and the anti-inflammatory IL-10 (Figure 2C-E). 
 
Pharmacological investigations using the MC3/4 antagonist SHU9119  
BMS-470539 is almost entirely selective for MC1, whilst [DTRP8]-γ-MSH may activate other 
MCs than MC38. To further examine the roles of specific MC subtypes, the MC3/4 antagonist 
SHU9119 was co-administered with either α-MSH or [DTRP8]-γ-MSH (Figure 3C and D), 
revealing that MC3/4 antagonism caused no increase in rolling or adhesion at 40min 
reperfusion vs. α-MSH or [DTRP8]-γ-MSH alone. In fact SHU9119 administered alone, or in 
conjunction with α-MSH, reduced neutrophil rolling. However by 2h, co-administration of 
SHU9119 blunted the α-MSH induced reductions in rolling and adhesion, and prevented the 
protective effects of [DTRP8]-γ-MSH.  
 
Melanocortin receptor expression 
To determine whether the delayed importance of MC3 was due to change in receptor 
expression antibody based investigations into receptor expression were undertaken. 
However initial analysis of MC1 and MC3 protein expression using western blotting revealed 
antibody binding in MC3-/- mice, using both the Sigma Aldrich (M4937) and Acris 
(AP10124PU-N) MC3 antibodies, despite PCR confirmation of the MC3-/- (Supplemental 
figure V). This suggests that both antibodies tested display non-specific binding to protein at 
a similar molecular weight to MC3, as has been previously described9. Therefore, qRT-PCR 
was used to quantify MC expression at the mRNA level. MC1,3,4&5, was detected in both 
blood and brain, however BCCAo induced no changes at either 40min or 2h following 
BCCAo (Supplemental Figure VI).  
 
Physiological effects of MC1 and 3 in cerebral I/R-induced inflammation 
We tested whether the physiological effects of receptor deficiency would support our findings 
from pharmacological treatments. Recessive yellow (e/e) MC1 mutant mice displayed 
enhanced (nearly 3 times) neutrophil rolling at 40min following I/R vs. WT (Figure 4A) 
accompanied by elevated serum TNF-α (Figure 4C). In the absence of a functional MC1, α-
MSH reduction of rolling was also hampered at this time point, however e/e mice displayed 
no derangements in cell adhesion and were able to respond to α-MSH treatment. MC3 null 
mice showed no significant differences in neutrophil recruitment, or in their ability to respond 
to α-MSH at 40min. This is consistent with the predominat anti-inflammatory role of MC1 at 
early reperfusion. In agreement with the diminished role of MC1 observed in pharmacological 
studies at 2h, at this time point the inflammatory phenotype was not maintained, with TNF-α 
levels and neutrophil rolling and adhesion being comparable to WT (Figure 5). 
 
Physiological role in focal stroke model 
 
Stroke is highly variable in its severity and magnitude. The global model of cerebral I/R, 
represents human stroke conditions caused by atherosclerotic degeneration of the common 
carotid arteries and respiratory or cardiac arrest. To investigate whether the MC anti-
inflammatory effects we were observing were specific to global I/R, we also undertook 
investigations using a focal stroke model (i.e. the middle cerebral artery occlusion (MCAo) 
model). We chose this model due to the fact that focal ischemia accounts for ~80% of 
ischemic stroke. Figure 6 demonstrates that at 24h post ischemia while e/e mice showed 
elevated adhesion, MC3-/- displayed a more severe inflammatory phenotype with significantly 
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enhanced rolling and adhesion. Importantly, the increased neutrophil recruitment observed, 
translated into elevated infarct volume and poor functional outcome (detected through 
neurological scoring) in animals with deficits in either receptor, suggesting both receptors to 
be potential pharmacological targets.  
 
In vitro investigations of melanocortin effects on neutrophil functioning 
The melanocortin receptor system displays a number of disparities between humans and 
rodents and a number of MC agonists and antagonists have different selectivity in MCs from 
different species8,10. To assess the effectiveness of melanocortin treatments on human cells, 
we utilized the neutrophil flow chamber model and chemotaxis assay to investigate 
neutrophil inflammatory function (Supplemental Figure VII). In the flow chamber, treating 
neutrophils with just 10µg/ml of α-MSH (a comparable dose to in vivo studies) resulted in 
significant reductions in capture (54% reduction) adherence (68%) and transmigration (67%) 
vs. saline (Supplemental Figure VIIA). Treating HUVECs with α-MSH (≤100µg/ml), however 
failed to induce significant reductions in neutrophil recruitment (data not shown), suggesting 
neutrophils to be the effector cells of MC actions in this context. In the chemotaxis assay, 
pre-treatment with 10µg/ml of α-MSH or [DTRP8]-γ-MSH failed to inhibit neutrophil migration 
towards fMLP, however BMS-470539 significantly reduced this response, suppressing the 
number of migrated cells by ~75% (Supplemental Figure VIIB), suggesting MC1 to play a 
specific role in inhibiting neutrophil chemotaxis. 
 
Discussion  
The present study provides, for the first time, evidence that melanocortin treatments can 
effectively inhibit neutrophil recruitment in the unique microenvironment of the cerebral 
microvasculature. Utilizing both selective ligands and MC mutant mice, we have gained an 
insight into MCs involved in modulating neutrophil recruitment in two separate models of 
cerebral I/R, finding both MC1 and MC3 to display important inhibitory roles. In addition, 
melanocortin treatment was effective in modulating human neutrophil inflammatory 
functioning, and may represent a novel treatment to stem post-stroke inflammation. 
 
Both ischemic models used (BCCAo and MCAo) here resulted in a pronounced increase in 
neutrophil rolling and adhesion compared to sham, as has previously been observed11,12. 
Non-selective treatment with α-MSH caused an abrogation of BCCAo-induced neutrophil 
rolling and adhesion, congruent with a trend toward a reduction in ICAM-1 and VCAM-1 
expression in the cerebral vascular. Considering these effects were not significant, other 
adhesion molecules and integrin activation state may also play a role in the melanocortin 
influence over leukocyte adhesion. While anti-ICAM-1 antibody Enlimomab failed clinical 
trials for stroke (possibly due to inflammatory side effects to the mouse monoclonal antibody) 
strategies inhibiting CAMs have shown great promise pre-clinically.  Soluble P and E-
selectin are early markers of endothelial activation. While levels of soluble P selectin were 
found only to produce a trend toward an increase following BCCAo which was unchanged by 
treatment, soluble E-selectin was increased by 2h post ischemia. Elevated levels of soluble 
E-selectin have been demonstrated in human stroke and during sepsis13. In vitro studies 
have also shown that endothelial cells stimulated with IL-1β, TNF-α, endotoxin or serum 
deprivation and TNF-α release E-selectin into the culture supernatant14,15. α-MSH treatment 
significantly reduced BCCAo induced soluble E-selectin, likely a reflection of reduced 
endothelial cell activation, consistent with the reduced levels of IL-1β and TNF-α observed. 
 
Treatment also reduced serum TNF-α and IL-1β. IL-1β in particular plays a pivotal role in 
propagating inflammatory responses and is an established pathological factor in 
cerebrovascular disease, with significant pre-clinical and clinical evidence demonstrating 
blockade of IL-1β signaling to be beneficial in stroke16. MSH treatment also simultaneously 
enhanced anti-inflammatory IL-10 by 2h reperfusion. The ability of MCs to suppress pro-
inflammatory responses whilst enhancing anti-inflammatory signals suggests that these 
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receptors form an endogenous pro-resolving system. In humans α-MSH concentrations 
increases in myocardial infarction and infection2 and higher melanocortin levels correlate 
with better outcome in stroke patients.17 Thus, given the results from the present study the 
melanocortin receptor system may prove a valuable therapeutic target for the treatment of 
stroke. 
 
While others have demonstrated a contribution of either MC1 or MC3 in providing anti-
inflammatory protection in different systemic inflammatory models, we have, for the first time, 
identified protective roles for both receptors in the cerebral-microvasculature. In particular, 
we have identified that MC1 mediated effects predominate in early protection, while MC3 
actions are more delayed and induce pro-resolving factors. This study reveals an additional 
layer of complexity in MC inflammatory modulation, emphasizing the importance of drug 
treatment directed at both receptors. 
 
Pharmacological investigations in the BCCAo model revealed the MC1 agonist BMS-470539, 
significantly inhibited early neutrophil rolling and adhesion, while activation of MC3 using [D-
TRP8]-γ-MSH only reduced adhesion. However by 2h following BCCAo, despite a robust 
pharmacodynamic half-life of ∼8 h18, BMS-470539 lost its inhibitory actions on rolling and 
the reduction of adhesion was diminished slightly. However at 2h, [D-TRP8]-γ-MSH anti-
inflammatory actions were enhanced. Thus suggesting MC3 mediated effects become more 
prominent at later time points. SHU9119 (MC3/4 antagonist) was used to further explore the 
role of MC subtypes. By 40min reperfusion, SHU9119 enhanced, rather than inhibited, α-
MSH and [D-TRP8]-γ-MSH effects. Furthermore, administered alone, SHU9119 reduced 
neutrophil adhesion at 40min, possibly due to its seldom reported agonist actions at MC1/510, 
further supporting the predominance of MC1 mediated effects at early stages of reperfusion. 
By 2h reperfusion SHU9119 lost these anti-inflammatory effects, and co-treatments with 
SHU9119 inhibited the protective effects of α-MSH and [D-TRP8]-γ-MSH, illustrating role for 
MC3 in mediating delayed effects on neutrophil adhesion.  
 
Despite the apparent change in MC engagement, no change in MC RNA expression was 
detected following BCCAo. Whether this is also reflected in protein expression is difficult to 
discern given the lack of specificity of the antibodies. Even if the surface expression of MC1 
or MC3 is increased following stroke, α-MSH and [D-TRP8]-γ-MSH have short half-lives and 
therefore are most likely exerting their effects before such up-regulation occurs. The Shift in 
receptor importance may instead reflect activation of distinct mechanisms of action and/or 
effector cells. Neutrophils express MC1, while MC3 expression is limited to endothelial cells 
and macrophages/monocytes. Rapid inhibitory actions exerted by MC1 may be through 
direct interactions with neutrophils, while the more prolonged MC3 actions are likely via 
actions on other effector cells. Inhibition of NF-κB is a key element of the protective MC 
actions2. Given NF-κB DNA binding occurs only after 30min following TNF-α stimulation, 
followed by gene transcription 30min later7, NF-κB inhibition is unlikely to mediate the rapid 
effects on neutrophil recruitment at 40min. Indeed IκB transcript levels were not significantly 
increased at 40min, yet by 2h blood IκB elevated 25-fold and nuclear levels of 
phosphorlyated NF-κB protein were enhanced, which was inhibited by α-MSH. Given our 
finding of the delayed effect of MC3 targeted treatment on neutrophil this later effect by α-
MSH on IκB may be mediated predominantly via MC3 signaling. 
 
Melanocortin treatments inhibited neutrophil recruitment at 40min after BCCAo, a timeframe 
incompatible with transcriptional changes. Such a phenomenon has previously been 
observed in other models; in zymosan stimulated macrophages AP214 reduced IL-1β and 
TNF-α release with no effect on mRNA levels19, and α-MSH can act via MC1 to shed cell 
surface CD14 on macrophages20 and IL-8 receptors on neutrophils21 independently of mRNA 
changes. While the understanding of NF-κB independent MC effects is still in its infancy, 
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these mechanisms may fit well with the early efficacy of MC1 treatments in suppressing 
neutrophil recruitment. 
 
Differences in cytokine regulation between MC1 targeted activation and MC3 targeted/non-
specific activation further support the hypothesis that MC1 and MC3 act via distinct 
mechanisms. Both α-MSH and [D-TRP8]-γ-MSH significantly reduced BCCAo induced TNF-
α whilst enhancing anti-inflammatory IL-10. TNF-α has multiple roles in stroke pathology and 
early increases in blood TNF have been shown to correlate with stroke severity in humans22 
while the anti-inflammatory cytokine IL-10 has been shown to be protective in a number of 
models of cerebral I/R23,24. BMS-470539 treatments however had no effect on these NF-κB 
controlled cytokines further supporting a distinct mechanism of action for the MC1 mediated 
early inhibition of neutrophil recruitment, while MC3 may be more prominent in initiating pro-
resolving effects. Conflicting reports have been made as the effect of melanocortin 
treatments on IL-6 levels, however in the current investigations both α-MSH and [D-TRP8]-γ-
MSH increased this pleiotropic cytokine at 2h, despite a decrease in NF-κB levels. As such 
the observed IL-6 release may be as a result of elevated release of pre-synthesized IL-6. α-
MSH has previously been shown to influence IL-6 levels via MC325, thus, explaining why IL-6 
induction was not observed in BMS-470539 treated animals. While IL-6 is an endogenous 
pyrogen with chemotactic activity, IL-6 KO mice show no protection following experimental 
stroke 26. Indeed IL-6 signaling via STAT3, has been shown to limit the inflammatory 
recruitment of neutrophils27, given that IL-10 may also activate STAT3 and levels were 
increased following α-MSH treatment such findings appear to be consistent with the present 
results. Furthermore it has been demonstrated that NF-κB signalling may induce expression 
of IL-6 and IL-10 in cells with a high level of STAT3 phosphorylation 28 In line with such 
observations we found nuclear extracts from α-MSH treated BCCAo animals to show a trend 
toward an elevation of phosphorylated STAT-3 protein.  
 
Our investigations using MC mutant mice, in two independent models of stroke, further 
support a temporal difference in MC1 and MC3 actions. Recessive yellow e/e mice displayed 
a transiently enhanced neutrophil rolling and elevated TNF-α at the very onset of the BCCAo 
induced inflammatory response, while MC3-/- mice showed no inflammatory phenotype at this 
early time point. It is possible that compensatory up regulation of other MCs may mask the 
anti-inflammatory role of this receptor in MC3-/-. Montero-Melendez et al., have previously 
shown that while in macrophages isolated from wild type and e/e zymosan challenge 
induced no change in MC1 MC3 or MC5 expression, in MC3−/− inflammatory challenge led to 
marked gene activation for MC1 and MC5 19 perhaps indicating compensatory regulation of 
other MC in the absence of MC3. However in the focal stroke model, at 24h MC3-/- animals 
displayed enhanced rolling and adhesion further supporting a delayed role of this receptor, 
while e/e animals only showed elevated adhesion compared to WT, perhaps as a result 
enhanced rolling prior to the observation period. Previous reports and unpublished data from 
our laboratory have shown no significant differences in the basal circulating levels of 
leukocytes between WT, e/e and MC3-/- 3. As such the observed enhanced leukocyte 
recruitment is unlikely to be due to an initially high leukocyte count in these animals. As 
observed in BCCAo animals both receptors appear to be of importance with MC3 anti-
inflammatory circuits predominating at later time points.  
 
Previously, Leoni et al., demonstrated that the MC3-/- mouse displays higher levels of 
leukocyte adhesion and emigration in the mesenteric microcirculation following I/R, while the 
response of the e/e mouse was not significantly different from WT 3. Yet in the same model 
the MC1 agonist BMS-470539 was effective in reducing leukocyte recruitment (an effect 
which was absent in e/e mice)4. These results led the authors to postulate that the receptors 
show different physiological roles but that both may be harnessed pharmacologically. The 
present findings demonstrate a physiological role for both receptors in the cerebral 
microcirculation. Indeed the observed of temporally distinct roles of these two receptors may 
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help to explain such apparently conflicting findings across studies investigating the anti-
inflammatory actions of these receptors. Crucially, our study demonstrates that the absence 
of signaling from either receptor resulted in enhanced infarct size and worse functional 
outcome compared to WT, further illustrating that both receptors are important 
pharmacological targets. 
 
Our studies have further demonstrated that melancortin peptides may effect neutrophil 
inflammatory functioning in human cells. As the melanocortin receptor system displays a 
number of disparities in organization and function between humans and rodents. Such as 
differences in potency and selectivity of melanocortin ligands, and receptor expression 
between species, we also investigated MC roles in human neutrophil functioning. The facts 
that α-MSH treatment was found to suppress neutrophil recruitment to HUVECs via actions 
on neutrophils, and that MC1, but not MC3, is expressed on neutrophils supports the concept 
of an MC1 specific effect. These effects were rapid, occurring within 30min following 
treatments, again a timeframe incompatible with transcriptional mechanisms. MC1 specific 
direct effects on neutrophils were further illustrated by the ability of MC1 targeted treatments 
to significantly reduce neutrophil chemotaxis (performed in the absence of other cell types). 
Further investigation however, will need to be made to establish the effector cell type of the 
delayed, but potent, effects of MC3 on neutrophil recruitment.  
 
Taken together, novel experimental data presented here highlights a role for utilization of 
melanocortin based treatments as potential therapeutics for stroke, and potentially other 
neurovascular diseases. This work also demonstrates important roles for both MC1 and MC3, 
showing MC1 effects to provide rapid inhibition of leukocyte recruitment via mechanisms 
independent of NF-κB regulation, while MC3 actions appear more robust at later time points. 
Given the complexity of MC regulation along with the variable nature of stroke, strategies 
targeting multiple MCs in a non-(or perhaps partially) selective manner may be more fruitful 
in providing robust protection, rather than targeting one MC alone. Indeed, it may be telling 
that currently the most promising melanocortin compounds (NDP-α-MSH and AP214) are 
both non-selective MC agonists. Further investigations into later time points of treatment and 
in animals with co-morbidities will help to reveal the full potential of this promising 
therapeutic target for stroke.  
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Significance 
Stroke is a leading cause of mortality and morbidity worldwide. Following the initial ischemic 
brain damage an ensuing inflammatory response may exacerbate injury. Neutrophils are key 
arbitrators of this damaging response and inhibiting neutrophil recruitment in cerebral 
ischemia reperfusion injury may provide therapeutic benefit. We have previously 
demonstrated that melanocortin treatments can reduce leukocyte recruitment in peripheral 
tissues, but these actions have yet to be demonstrated in the unique microcirculation of the 
brain. Here in, we show that melanocortins reduce post ischemic leukocyte recruitment in 
the brain, and that these effects are mediated by the distinct actions of both melanocortin 
receptors 1 and 3. Therefore, targeting these receptors provides a novel therapeutic strategy 
for treating stroke, and other cerebrovascular diseases. 
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Figure Legends 
Figure 1. BCCAo induces leukocyte recruitment, which is abrogated by α-MSH 
treatment. A) representative IVM video stills show interactions of leukocytes (white arrow) 
on  the cerebral vessel wall, with clearly observable increases following BCCAo. Images 
taken on an Olympus BW61WI microscope, magnification x 40. B-C) Leukocyte recruitment 
in the cerebral microcirculation was quantified in terms of: (B) number of cells rolling along 
the vessel wall per mm2 (termed rolling cell flux); and C) those cells stationary for 30sec or 
longer (Adhesion: cells/mm2/min). Values represent mean ± SEM. n=6 mice/group. * 
denotes significance to sham *P<0.01,**P<0.001. † = significance to saline treated BCCAo 
group P<0.01, †† P<0.001.  ‡ = significant increase to 40min reperfusion group. P<0.05 is 
considered significant  
Figure 2. The effect of pharmacologically selective treatments on L-E interactions and 
circulating cytokines. Leukocyte recruitment in the cerebral microcirculation was quantified 
in terms of: A) rolling cell flux and B) adhesion (cells/mm2/min), at either 40min or 2h 
following 5min BCCAo. Treatments were given i.p. at the start of reperfusion using either the 
MC1 selective BMS-470539 (BMS) or the MC3 agonist [D-TRP8]-γ-MSH (DTRP). Values 
represent mean ± SEM. Statistical analysis was performed across different treatments within 
the same time of reperfusion. n=6 mice/group. * denotes significance to sham 
P<0.01,**P<0.001, † denotes significance to saline treated BCCAo group P<0.01, †† 
P<0.001. Serum levels of circulating cytokines C)TNF-α, D) IL-6 and E) IL-10 were assessed 
using a cytometric bead array, n=3 mice/group and performed in duplicate. 
Figure 3. Effects of MC3/4 antagonism on the actions of α-MSH and [D-TRP8]-γ-MSH. 
Leukocyte recruitment in the cerebral microcirculation was quantified in terms of: rolling cell 
flux and adhesion (cells/mm2/min), following BCCAo and 40min or 2h reperfusion. Affect of 
the MC3/4 antagonist SHU9119 when administered 10µg i.p at the start of reperfusion on A) 
leukocyte rolling cell flux and B) leukocyte adhesion. Leukocyte rolling C) and adhesion D) 
was also assessed in mice treated with either α-MSH or [D-TRP8]-γ-MSH alone (10µg) or in 
combination with SHU9119 (10µg). α-MSH 40min co-treatment group n=6 mice/group all 
other co-treatment groups n=4. Comparisons were made to singular treatment groups from 
Figure 2. Statistical analysis was performed comparing different treatments within the same 
time of reperfusion. † represents statistical significance to saline treated BCCAo group 
P<0.01. †† = P<0.001  
Figure 4. Mice bearing a non-functional MC1 display acutely enhanced L-E 
interactions and TNF-α levels following I/R. Wild type C57BL/6 (white bars), MC1 mutant 
e/e (lined bars) and MC3-/- (checked bars) mice were subjected to sham or BCCAo surgery 
with 40min reperfusion and treatment with either saline or 10µg α-MSH at the start of 
reperfusion. Leukocyte recruitment in the cerebral microcirculation was quantified in terms 
of: A) rolling cell flux and B) adhesion (cells/mm2/min). WT groups n=6 mice/group, e/e and 
MC3-/- sham and MC3-/- α-MSH groups n=3 all other groups n=4 mice/group. C) ELISA 
measurements of serum TNF-α levels n=3 mice/group and performed in duplicate. Statistical 
analysis was performed between mouse strains, within sham or saline treated groups to 
determine the phenotypic differences between strains, ‡ denotes significance to WT P<0.01. 
Statistical analysis was also performed between sham, saline and α-MSH treatment groups 
within the same strain. * shows significance to sham group P<0.05 and † shows significance 
to saline treated BCCAo group P<0.05.  
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Figure 5. The e/e mouse inflammatory phenotype is diminished by 2h. WT (C57BL/6) 
(white bars) and e/e (lined bars) mice were subjected to sham or BCCAo and treated with 
saline or 10µg α-MSH at the start of reperfusion. Leukocyte recruitment was quantified at 2h 
of reperfusion in terms of: in terms of: A) rolling cell flux and B) leukocyte adhesion 
(cells/mm2/min). n = 4 mice/group for e/e saline group, and n=3 mice/group for sham and α-
MSH e/e groups, comparisons were made to WT groups as in figure 1 (n=6 mice/group). 
Statistical analysis was performed between mouse strains, within the same treatment group 
to evaluate phenotypic differences between strains. NS denotes no statistical significance to 
WT group. C) ELISA measurements of serum TNF-α in WT and e/e mice. * denotes 
significance to sham groups P<0.01, † denotes significance to BCCAo P<0.05.  
Figure 6. Physiological role of MC1 and MC3 in focal cerebral I/R. (A and B) Leukocyte 
recruitment in the cerebral microcirculation was quantified following MCAo and 24h 
reperfusion in terms of: rolling cell flux and leukocyte adhesion (cells/mm2/min). C) Infarct 
volume and D) Neurological score were also assessed. Values represent mean ± SEM. n=4-
6 mice/group. * denotes significance to corresponding sham group, +denotes significance to 




Supplemental Figures and Figure Legends 
 
 
Supplemental Figure I. Effects of PMN depletion on cerebral I/R induced leukocyte 
recruitment. (A) C57BL/6 mice were treated with either anti-mouse PMN serum or IgG 
matched serum (10ml/kg, i.p.) once daily for two consecutive days. Tail vein blood samples, 
for total white cell count and differential cell counts, were collected pre-treatment and post 
treatment. Anti-PMN treatment reduced total PMN count by ~85%. ** denotes significant to 
Anti-PMN pre-treatment group P<0.001. (B-C) Following sham or BCCAo and 40min 
reperfusion, IVM was used to assess leukocyte recruitment in the cerebral microcirculation in 
terms of: (B) number of cells rolling along the vessel wall per mm
2
 (termed rolling cell flux) 
and (C) those cells stationary for 30sec or longer (termed adhesion: cells/mm2/min). 
Depleting mice of neutrophils was found to significantly inhibit the number of observed 
leukocytes interacting with venules of the cerebral microcirculation. † denotes statistical 
significance to IgG group P<0.01. Values represent mean ± SEM. All IgG and anti-PMN 





















Supplemental Figure II. Modulation of adhesion molecule expression. (A and B) levels 
of circulating soluble P and E selectin were measured in serum samples showing enhanced 
P-selectin levels by 2h reperfusion which were suppressed by α-MSH treatment. (C and D) 
the cerebral microcirculation was stained for ICAM-1 and VCAM-1 adhesion molecules, 
BCCAo was found induce a trend toward an increase in the number of ICAM-1 and VCAM-1 
positive vessels compared to sham with α-MSH treatment showing a modest trend toward a 
reduction. (E and F) Representative x20 micrographs of cerebral vessels stained for vWF 
(red) and ICAM-1 (green) or vWF (Green) and VCAM-1(Red).  
  
  
Supplemental Figure III. Cytokine response to BCCAo and α-MSH treatment. (A-C) 
CBA was used to quantify circulating serum cytokine levels (IL-6, IL-10, MCP-1, IFN-γ, TNF-
α, and IL-12p70) and ELISA used to detect IL-1β levels following BCCAo and MSH 
treatment at both 40min and 2h reperfusion. Expression of IL-12p70, IFN-γ and MCP-1 
remained below the reliable detection range across all treatments (Data not shown). 
However BCCAo induced significant increases in TNF-α and IL-1β by 2h, which was 
abrogated by α-MSH treatment. Treatment also induced significant increases in the 
pleiotropic cytokine IL-6 and the anti-inflammatory IL-10 at 2h. n=3 for all groups. * denotes 







Supplemental Figure IV. NF-κB and STAT-3 activation. NF-κB activation was assessed 
by quantifying mRNA levels of IκB using qRT-PCR in (A) blood and (B) brain. To further 
investigate the NF-κB activation in blood, leukocyte protein levels of the serine 536 
phospholyated form of NF-κB in nuclear fractions were detected using western blot (C and 
D). NF-κB activation as detected by protein level at 2h reflected IkB RNA levels (C). 
Considering IL-10 and IL-6 can activate protective STAT-3 pathways the level of STAT-3 
activation in leukocytes was also assessed using western blot at 2h (D).  n=3 for all groups. * 




Supplemental Figure V. MC3 antibodies show binding in tissue from mice lacking the 
MC3 transcript. (A) PCR analysis demonstrates the absence of MC3 RNA transcript in 
samples from MC3-/- mice. (B) Western blot analysis with two separate MC3 antibodies 
produce bands at the correct height in brain homogenates from both wild type and MC3-/- 
mice suggesting non-specific binding to other melanocortin receptors or unrelated proteins of 




Supplemental Figure VI. BCCAo does not alter melanocortin receptor mRNA 
expression. Total blood RNA was isolated from whole blood (A) or brain (B) of C57BL/6 
mice subjected to Sham surgery or BCCAo with reperfusion times of 40min or 2h. qRT-PCR 
used to quantify the mRNA levels of MC1 MC3 MC4 and MC5. Values represent mean ± SEM 
of fold change in expression compared to 40min sham operated control. n=3 for all groups, 
no significant changes were detected. 
  
  
Supplemental Figure VII. Melanocortin peptides directly affect human neutrophil 
functioning. (A) Human neutrophils (1x106 cells/ml) were perfused over TNF-α stimulated 
(10ng/ml, 4h) confluent HUVEC monolayers. Neutrophils were pre-treated with saline or 
10µg/ml of α-MSH. Leukocyte recruitment was quantified in terms of Capture (all cells 
interacting with the monolayer), number of rolling cells, adherent cells (cells stationary for 
10sec or longer) and number of cells transmigrating across the HUVEC monolayer, n=4 for 
all groups. (B) Levels of neutrophil chemotaxis found to migrate across a porous membrane 
toward the chemoattractant FMLP (10nM). Neutrophils (4x106 cells/ml) were pre-treated 
10min with 10µg/ml α-MSH, BMS-470539 or [D-TRP8]-γ-MSH then applied to the membrane 
and incubated for 1.5h before assessing neutrophil migration. Control fMLP and α-MSH 
groups n=5, all other groups n=3. * denotes significance to un-stimulated group P<0.05. **= 
P<0.001. † denotes significance to saline treated group, P < 0.05, †† = P< 0.001 
  
Supplemental Video legends 
 
Supplemental video I 
Intravital video clip of a representative pial brain vessel of a sham treated C57BL/6 mouse. 
Demonstrating a single adherent leukocyte within the vessel. 
Supplemental video II 
Intravital video clip of a representative pial brain vessel from a BCCAo 2h reperfusion saline 
treated C57BL/6 mouse demonstrating rolling and adhesion of leukocytes within the vessel  
 
Materials and Methods 
 
Animals 
All Housing conditions and experimental procedures were in strict accordance with Home 
Office Regulations (Scientific Procedures Act, 1986) and the European Directive 
2010/63/EU. All animals were used at 18-30g body weight. Male C57BL/6 mice were 
supplied by Charles River (Kent, UK), recessive yellow (e/e) mice are the result of a natural 
mutation causing a single nucleotide deletion at position 549 and were supplied by Prof. 
Mauro Perretti at the William Harvey Research Institute, London. The MC3-/- colony, 
backcrossed for six generations onto a homogenous C57Bl6 background(1), were kindly 
donated by Dr. H. Chen (Merck Research Laboratories, NJ, USA) and bred at the William 
Harvey Research Institute, London. Animals were maintained on a 12h/12h light/dark cycle 
with an ambient temperature between 21-23°C with access to standard chow pellet diet and 
water ad libitum. 
  
Drug treatments 
The pan receptor agonist α-MSH (Asc-189, Ascent Scientific, Cambridge, UK) the MC3 
partially selective agonist [DTRP8]-γ-MSH (4272, Tocris, Bristol, UK), the MC1 selective 
agonist BMS-470539 (4053, Tocris, Bristol, UK) and the MC3/4 antagonist SHU9119 (3420, 
Tocris, Bristol, UK) were utilized in this study. Drug treatments were all administered at the 
start of reperfusion by intraperitoneal (i.p) injection at 10µg in 100µl saline, with the 
exception of BMS-470539, which was given at 9.4mg/Kg. Drug dose was chosen with 
regards to optimal doses in the literature(2-6). Treatments were given at the start of 
reperfusion. 
Global Stroke Model: bilateral common carotid artery occlusion (BCCAo) 
Following anaesthesia (100mg/kg pentobarbital i.p, Merial, Essex, UK), the animals 
temperature was monitored using a rectal thermometer and maintained throughout the 
procedure as close to 37.5 oC as possible using a heat mat. The common carotid arteries, 
exposed and occluded using aneurysm clips(7). Following 5min of occlusion clips were 
removed to allow for reperfusion. Sham animals omitted BCCAo. 
  
Focal Cerebral I/R Model: Middle Cerebral Artery Occlusion (MCAO) 
Animals were anaesthetized with. ketamine (150 mg/kg i.p.; Fort Dodge Animal Health, 
Southampton, UK) and xylazine (7.5 mg/kg i.p.; Bayer Healthcare, Newbury, UK) and body 
temperature maintained as above. The middle cerebral artery (MCA) was occluded using the 
intraluminal filament method (8), using a 60min occlusion period followed by a period of 24h 
reperfusion. Sham-operated mice were subject to the same surgical procedures omitting 
MCA occlusion.  
 
Intravital Microscopy (IVM) 
A crainotomy was performed and rhodamine-6G (100µl, 0.02% in saline) injected through a 
jugular vein cannula to fluorescently label circulating leukocytes. The cerebral 
microcirculation visualized using intravital microscopy (IVM) as described previously(8). Off-
line analysis of leukocyte-endothelium interactions yielded: ‘rolling cell flux’ (number of cells 
passing a fixed point/minute) and ‘adhesion’ (cells remaining stationary for 30sec or longer) 
and calculated as cells/mm2 of vessel/min as described previously(8). 
Infarct Volume 
After reperfusion (24h), MCAo mice were sacrificed, brains removed and placed into 4°C 
PBS for 15min. 2mm coronal sections were cut with a tissue cutter, and sections stained 
with 2% 2,3,5-triphenyltetrazolium chloride in phosphate buffer for 15min followed by fixation 
in 10% formaldehyde. Sections were photographed and the infarct area quantified in 
digitized images using NIH Image Software version 1.57.  
Neurological score 
The functional consequences of cerebral 24h I/R injury were evaluated using a five-point 
neurological deficit score: 0=no deficit; 1=failure to extend right paw; 2=circling to the right; 
3=falling to the right; and 4=unable to walk spontaneously (8). 
 
Neutrophil depletion 
Anti-mouse PMN serum or serum matched control (AIA31140 and AIS403, Gentaur, 
London, UK) diluted 1:10 in saline and used at 10ml/kg was administered (i.p) daily for two 
days prior to BCCAo surgery. PMN depletion was confirmed 48h following injection by total 
white blood cells count in Turk's solution. WBC differential counts were obtained from blood 
smears stained with Wright-Giemsa. Both counts were compared with samples taken prior to 
treatment and in all cases PMNs were found to be depleted by >85% 
 
Immunofluorescent staining  
Experimental animals were perfused with saline followed by 4% paraformaldehyde and 
brains cyroprotected in 20% sucrose for 18h before freezing in isopentane and embedded in 
OCT (Sakura). 18µm coronal cryostat sections	  taken between 1mm and 3mm posterior to 
the bregma and mounted on	  charged microscope slides before being stored at -20 °C. 
Sections were hydrated in PBS for 5min, before performing heat mediated antigen retrieval 
with Vector Laboratories' Antigen Unmasking Solution for 10min. Blocking was then 
performed in PBS +1% BSA and 10% serum for 2h. Sections were rinsed in TBST before 
adding the primary antibodies Rat anti-ICAM-1 (ab119871, Abcam) and Rabbit anti-vWF 
(A0082, Dako); or Rabbit anti VCAM-1(SC-8304, Santa Cruz) and Sheep anti -vWF 
(ab11713, Abcam) overnight at 4oC. Sections were incubated with secondary antibodies 
(Alexa Fluor 546 Donkey Anti-Rabbit IgG, 1:200) for 2h at room temperature. Sections were 
counterstained with DAPI and imaged using a Nikon Eclipse inverted microscope with Nikon 
Elements acquisition software. Number of vessels between 10-100µm in diameter found to 
be I-CAM or V-CAM positive across 5 x20 fields of view per section were expressed as a 
ratio of total number of vessels observed (vWF positive).     
 
Quantitative Real-Time PCR  
Quantitative Real-Time PCR (qRT-PCR) was employed to measure the expression of MCs1-
5, TNF-α and IκB-α mRNA in both brain and blood samples from experimental mice. Total 
RNA was isolated from whole brain and blood using an RNeasy RNA purification kits 
(Qiagen).  
 
qRT- PCR was performed using QuantiFast SYBR green one-step RT-PCR kit (Qiagen) with 
QuantiTect primer assays, containing Quiagen forward/reverse primers for MC1 
(QT00305011), MC3 (QT00264404), MC4 (QT00280861) and MC5 (QT01166494) and IκB 
(QT00134421). A panel of reference genes were tested for coefficient of variance and 
TATAA-box binding protein (QT00198443) was found to be the most suitable, and was thus 
as an internal control. Reactions containing 50ng of template RNA were run in triplicate 
using an MX3000P real time cycler (Stratagene) Fluorescence data collection was 
performed during the annealing/extension phase. Dissociation curves, performed at the end 
of each reaction confirmed the presence of a single PCR product. Relative quantification of 
gene expression was determined using the ∆∆CT method as previously described8. 
 
ELISA 
Serum from blood samples taken by cardiac puncture were stored at -80°C until use. 
Quantikine® Colorimetric TNF-α, IL-1β, soluble E-selectin and soluble P-selectin ELISA kits 
(R&D Systems, Oxfordshire, UK) were used for the analysis of serum proteins according to 
the manufactures guidelines.  
 
Cytometric Bead Array 
Quantitative detection of IL-6, IL-10, MCP-1, IFN-γ, TNF-α, and IL-12p70 was performed on 
mouse serum samples using a BD Cytometric Bead Array (CBA) Mouse Inflammation Kit 
(552364, BD Biosciences, Oxfordshire, UK), and assessed using a dual laser BD 
FACSCalibur, with BD CellQuest pro software for acquisition. 
 
Western blot 
Western blots were performed on whole brain homogenates or leukocyte nuclear fractions 
obtained using active motif nuclear extract kit. Rabbit anti mouse MC3 antibodies were used 
to detect brain MC3 expression (Sigma Aldrich M4937 and Acris AP10124PU-N). For 
investigation of transcription factor activation in leukocytes rabbit anti-phospho S536 NF-κB 
p65 (ab86299, Abcam) antibody was used to detect NF-κB activation, whilst rabbit anti 
phospho Y705 STAT-3 antibody was used to detect STAT activation. Horse radish 
peroxidase conjugated anti-rabbit antibody was used as the secondary and protein 
expression determined by densitometry using Image J software and normalized to α-tubulin 
or GAPDH expression. 
 
Human neutrophil isolation  
Due to differences in MC biology between humans and rodents investigations were also 
undertaken using human neutrophils. Blood collection and leukocyte isolation was performed 
with ethical approval from the National Health Service Research Ethical Committee 
(2009,04/Q0401/40). Samples were taken from healthy individuals, with no history of recent 
acute or chronic illness, and neutrophils were isolated using a density gradient, as described 
previously(9).  
 
Flow chamber leukocyte recruitment assay 
For investigations into human neutrophil recruitment human umbilical vein endothelial cells 
(HUVECs) were seeded (2.5x106cells/ml) in µ-Slide VI0.4 flow chamber slides (IBIDI, Munich, 
Germany) and grown to confluence before stimulating with TNF-α (10ng/mL) for 4h prior to 
flow. HUVECs were treated with α-MSH (1-100µg/ml) or vehicle 2h prior to flow. Isolated 
neutrophils (1x107cells/ml) were either pre-treated with vehicle or 10µg/ml α-MSH 30min 
before flow. Neutrophils were perfused over HUVECS at a shear stress of 1dyne/cm2 and 
number of rolling, firmly adherent (cells stationary for ≥10sec) and transmigrated cells (cells 
changing from phase bright to dark) recorded as previously described(9) 
Neutrophil chemotaxis assay 
Chemotaxis assays were performed using neuroprobe 96-well disposable plates (Neuro 
Probe Inc.). Neutrophils (4x106 cells/ml) were incubated for 10min at 37.5°C, 5% CO2 either 
with RPMI or α-MSH, BMS-470539 or [DTRP8]-γ-MSH (10µg/ml) in RPMI. fMLP 10-6M in 
RPMI + 0.1% BSA was used as a chemo-attractant and placed in the bottom wells. The top 
chamber was filled with 25µL of neutrophils. Plates were incubated for 1.5h (37.5°C, 5% 




Data are expressed as mean +/- SEM. Results from intravital microscopy experiments were 
confirmed to follow a normal distribution using Kolmogorov-Smirnov test of normality with 
Dallal-Wilkinson-Lilliefor corrected P Value. Data that passed the normality assumption was 
analyzed using Student’s t-test or ANOVA with Bonferroni post-tests, which were performed 
using GraphPad Prism5 software. Data that failed the normality assumption were analyzed 
using the non-parametric Mann-Whitney U test. Data are shown as mean values ± standard 
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